Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
NTIntellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA)

NASDAQ Global Market · Currency in USD
$11.21 ▲ +0.05 (+0.45%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.27 ▲ +0.06 (+0.54%)
Pre-market: Oct 26, 8:13 AM ET

Summary

Previous Close
$11.16
Open
$11.00
Day's Range
$10.58 – $11.24
52 Week Range
$7.95 – $18.48
Volume
3,566,569
Avg. Volume
4,568,310
Market Cap
$1.57B
Beta (5Y Monthly)
1.80
PE Ratio (TTM)
--
EPS (TTM)
-$3.00
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.64

Profile: Intellia Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
377
CEO
John Leonard

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.80 · Revenue est. $9.74M
DateEst.Actual
Aug 6, 2026-$0.80-$0.80Miss
May 11, 2026-$0.92-$0.81Beat
Feb 26, 2026-$0.99-$0.83Beat
Nov 6, 2025-$1.02-$0.92Beat
Aug 7, 2025-$1.03-$0.99Beat
May 8, 2025-$1.26-$1.10Beat

Analyst view

Consensus price target
$21.64 ▲ +93.0%
Range $8.00 – $49.00
Rating: Buy
Buy 74% · Hold 18% · Sell 8%

Get free alerts on NTLA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.